| Name | Title | Contact Details |
|---|
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
Block Drug Company Inc. is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
MacroCap Labs is a contract manufacturing company founded in 2010. With steady improvements in quality and capacity, we have become one of the top contract manufacturers in the state of Florida. Our FDA registered facility ensures that we meet or excee...
Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation`s leading ophthalmology outsourcing facility and pharmaceutical compounding business.
Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical